Difference between revisions of "Team:BIT/nb"

Line 93: Line 93:
 
<br>
 
<br>
  
−
iii. week4(2017.03.25-2017.03.31)</span><br>
+
iii. week 4(2017.03.25-2017.03.31)</span><br>
 
   &nbsp;&nbsp;&nbsp;
 
   &nbsp;&nbsp;&nbsp;
 
We chose our main experimental method.<br>
 
We chose our main experimental method.<br>
Line 101: Line 101:
  
  
−
    <p>&nbsp;</p>
+
      <p>&nbsp;</p>
 
<p><span class="label-warning"><font size=4><font color=black> April: </font> </font></span></p>
 
<p><span class="label-warning"><font size=4><font color=black> April: </font> </font></span></p>
−
   <span class="lead">&nbsp;&nbsp;
+
   </span><p>&nbsp;&nbsp;<br>
−
<p>
+
i. Week 5(2017.04.01-2017.04.07)
−
i. Strength:
+
−
  </span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; 1. Convenience.
+
−
  <br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2. Adaptability.
+
−
  <br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; 3. High Cost/Performance Ratio.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  4. Inelastic to change in test conditions.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  ii. Weakness:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  1. Technology Barrier.
+
 
<br>
 
<br>
−
   &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
   &nbsp;&nbsp;&nbsp;  
−
  2. Branding Barrier.
+
We listed the plasmids we might use, designed the gene lines, began to construct our part.
 +
 
 
<br>
 
<br>
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
ii. Week 6(2017.04.08-2017.04.14)
−
  3. Strict Market Admittance Criteria.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  4. Distribution Barrier.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  iii. Opportunity:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  1. Favorable national economic condition.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  2. Positive national policies.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  3. Uprising Health-consciousness.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  iv. Threats:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  1. Well-established industries control the high-end markets with related products.
+
 
<br>
 
<br>
−
   &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;
+
   &nbsp;&nbsp;&nbsp;  
−
  2. Industrial chain is currently complete
+
We constructed our first part BBa_K2305008.
 
<br>
 
<br>
−
   &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
 
−
  3. Technological applications are matured</p>
+
iii. Week 7(2017.04.15-2017.04.21)
 +
<br>
 +
   &nbsp;&nbsp;&nbsp;
 +
We constructed our part BBa_K2305011、BBa_K2305012 and BBa_K2305003、BBa_K2305002.<br>
 +
 
 +
iv.    Week 8(2017.04.22-2017.04.28)
 +
<br>
 +
  &nbsp;&nbsp;&nbsp;
 +
We import BBa_K876070 to E.coli, detect the growth and fluorescence curve of E.coil under various lysine concentration.<br>
 +
</p>
  
 
     <p>&nbsp;</p>
 
     <p>&nbsp;</p>
Line 191: Line 173:
 
<p><span class="label-warning"><font size=4><font color=black> June: </font> </font></span></p>
 
<p><span class="label-warning"><font size=4><font color=black> June: </font> </font></span></p>
 
   <span class="lead">&nbsp;&nbsp;
 
   <span class="lead">&nbsp;&nbsp;
−
<p> 
+
 
−
i. Strength:
+
−
  </span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; 1. Convenience.
+
−
  <br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2. Adaptability.
+
−
  <br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; 3. High Cost/Performance Ratio.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  4. Inelastic to change in test conditions.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  ii. Weakness:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  1. Technology Barrier.
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  2. Branding Barrier.
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  3. Strict Market Admittance Criteria.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  4. Distribution Barrier.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  iii. Opportunity:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  1. Favorable national economic condition.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  2. Positive national policies.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  3. Uprising Health-consciousness.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  iv. Threats:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  1. Well-established industries control the high-end markets with related products.
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;
+
−
  2. Industrial chain is currently complete
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  3. Technological applications are matured</p>
+
−
    <p>&nbsp;</p>
+
−
<p><span class="label-warning"><font size=4><font color=black> July: </font> </font></span></p>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
<p> 
+
−
i. Strength:
+
−
  </span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; 1. Convenience.
+
−
  <br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2. Adaptability.
+
−
  <br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; 3. High Cost/Performance Ratio.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  4. Inelastic to change in test conditions.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  ii. Weakness:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  1. Technology Barrier.
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  2. Branding Barrier.
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  3. Strict Market Admittance Criteria.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  4. Distribution Barrier.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  iii. Opportunity:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  1. Favorable national economic condition.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  2. Positive national policies.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  3. Uprising Health-consciousness.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  iv. Threats:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  1. Well-established industries control the high-end markets with related products.
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;
+
−
  2. Industrial chain is currently complete
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  3. Technological applications are matured</p>
+
−
    <p>&nbsp;</p>
+
−
<p><span class="label-warning"><font size=4><font color=black> August: </font> </font></span></p>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
<p> 
+
−
i. Strength:
+
−
  </span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; 1. Convenience.
+
−
  <br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2. Adaptability.
+
−
  <br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; 3. High Cost/Performance Ratio.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  4. Inelastic to change in test conditions.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  ii. Weakness:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  1. Technology Barrier.
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  2. Branding Barrier.
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  3. Strict Market Admittance Criteria.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  4. Distribution Barrier.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  iii. Opportunity:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  1. Favorable national economic condition.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  2. Positive national policies.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  3. Uprising Health-consciousness.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  iv. Threats:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  1. Well-established industries control the high-end markets with related products.
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;
+
−
  2. Industrial chain is currently complete
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  3. Technological applications are matured</p>
+
−
    <p>&nbsp;</p>
+
−
<p><span class="label-warning"><font size=4><font color=black> September: </font> </font></span></p>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
<p> 
+
−
i. Strength:
+
−
  </span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; 1. Convenience.
+
−
  <br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2. Adaptability.
+
−
  <br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; 3. High Cost/Performance Ratio.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  4. Inelastic to change in test conditions.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  ii. Weakness:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  1. Technology Barrier.
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  2. Branding Barrier.
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  3. Strict Market Admittance Criteria.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  4. Distribution Barrier.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  iii. Opportunity:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  1. Favorable national economic condition.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  2. Positive national policies.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  3. Uprising Health-consciousness.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  iv. Threats:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  1. Well-established industries control the high-end markets with related products.
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;
+
−
  2. Industrial chain is currently complete
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  3. Technological applications are matured</p>
+
−
    <p>&nbsp;</p>
+
−
<p><span class="label-warning"><font size=4><font color=black> October: </font> </font></span></p>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
<p> 
+
−
i. Strength:
+
−
  </span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; 1. Convenience.
+
−
  <br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2. Adaptability.
+
−
  <br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; 3. High Cost/Performance Ratio.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  4. Inelastic to change in test conditions.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  ii. Weakness:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  1. Technology Barrier.
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  2. Branding Barrier.
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  3. Strict Market Admittance Criteria.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  4. Distribution Barrier.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  iii. Opportunity:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  1. Favorable national economic condition.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  2. Positive national policies.<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+
−
  3. Uprising Health-consciousness.<br>
+
−
  <span class="lead">&nbsp;&nbsp;
+
−
  iv. Threats:</span><br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  1. Well-established industries control the high-end markets with related products.
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;
+
−
  2. Industrial chain is currently complete
+
−
<br>
+
−
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;
+
−
  3. Technological applications are matured</p>
+
 
   
 
   
 
</div>
 
</div>

Revision as of 20:46, 31 October 2017

Journal

 

March:

  
i. Week 1-2(2017.03.04-2017.03.17)
    After discussion, the main goal of our project was to detect cancer of the liver by using small molecule
ii. Week 3(2017.03.18-2017.03.24)
    After reviewing the literature, we chose lysine as our small molecule and chose lysine-deficient E.coli as our bacteria.
iii. week 4(2017.03.25-2017.03.31)
    We chose our main experimental method.

 

April:

  
i. Week 5(2017.04.01-2017.04.07)
    We listed the plasmids we might use, designed the gene lines, began to construct our part.
ii. Week 6(2017.04.08-2017.04.14)
    We constructed our first part BBa_K2305008.
iii. Week 7(2017.04.15-2017.04.21)
    We constructed our part BBa_K2305011、BBa_K2305012 and BBa_K2305003、BBa_K2305002.
iv. Week 8(2017.04.22-2017.04.28)
    We import BBa_K876070 to E.coli, detect the growth and fluorescence curve of E.coil under various lysine concentration.

 

May:

  

i. Strength:
         1. Convenience.
         2. Adaptability.
         3. High Cost/Performance Ratio.
         4. Inelastic to change in test conditions.
   ii. Weakness:
         1. Technology Barrier.
         2. Branding Barrier.
         3. Strict Market Admittance Criteria.
         4. Distribution Barrier.
   iii. Opportunity:
         1. Favorable national economic condition.
         2. Positive national policies.
         3. Uprising Health-consciousness.
   iv. Threats:
        1. Well-established industries control the high-end markets with related products.
        2. Industrial chain is currently complete
        3. Technological applications are matured

 

June:

  

Hire Us!

Facilis ipsum reprehenderit nemo molestias. Aut cum mollitia reprehenderit. Eos cumque dicta adipisci architecto culpa amet.

Contact Us